Cargando…
The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
Jonathan D. Glass, M.D., is leading a clinical trial testing the safety of using adult stem cells to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that remains untreatable. This trial, along with others like it, is just the beginning of a time-intensive process...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Dana Foundation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574778/ https://www.ncbi.nlm.nih.gov/pubmed/23447769 |
_version_ | 1782259636623114240 |
---|---|
author | Glass, Jonathan D. |
author_facet | Glass, Jonathan D. |
author_sort | Glass, Jonathan D. |
collection | PubMed |
description | Jonathan D. Glass, M.D., is leading a clinical trial testing the safety of using adult stem cells to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that remains untreatable. This trial, along with others like it, is just the beginning of a time-intensive process necessary to determine whether stem-cell treatments are safe and effective, meaning that the benefits—if there prove to be any—outweigh the risks. But even as FDA-approved trials are underway, some people with neurodegenerative disorders are turning to dangerous, unapproved stem-cell treatments out of desperation. Dr. Glass warns that researchers must strictly adhere to the scientific process in order to convert the hope of stem-cell treatments into reality. |
format | Online Article Text |
id | pubmed-3574778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | The Dana Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35747782013-02-27 The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases Glass, Jonathan D. Cerebrum Article Jonathan D. Glass, M.D., is leading a clinical trial testing the safety of using adult stem cells to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that remains untreatable. This trial, along with others like it, is just the beginning of a time-intensive process necessary to determine whether stem-cell treatments are safe and effective, meaning that the benefits—if there prove to be any—outweigh the risks. But even as FDA-approved trials are underway, some people with neurodegenerative disorders are turning to dangerous, unapproved stem-cell treatments out of desperation. Dr. Glass warns that researchers must strictly adhere to the scientific process in order to convert the hope of stem-cell treatments into reality. The Dana Foundation 2010-12-15 /pmc/articles/PMC3574778/ /pubmed/23447769 Text en Copyright 2010 The Dana Foundation All Rights Reserved |
spellingShingle | Article Glass, Jonathan D. The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases |
title | The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases |
title_full | The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases |
title_fullStr | The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases |
title_full_unstemmed | The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases |
title_short | The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases |
title_sort | promise and the reality of stem-cell therapies for neurodegenerative diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574778/ https://www.ncbi.nlm.nih.gov/pubmed/23447769 |
work_keys_str_mv | AT glassjonathand thepromiseandtherealityofstemcelltherapiesforneurodegenerativediseases AT glassjonathand promiseandtherealityofstemcelltherapiesforneurodegenerativediseases |